中国中西医结合消化杂志2024，Vol.32Issue(2) ：134-138,150.DOI:10.3969/j.issn.1671-038X.2024.02.09

葛芩消溃方联合美沙拉嗪治疗溃疡性结肠炎疗效及相关机制初步探讨

Preliminary study on the efficacy and related mechanisms of Geqin Xiaokui Formula combined with mesalazine in the treatment of ulcerative colitis

贾靖 徐甜甜 张毅 汪洋
中国中西医结合消化杂志2024，Vol.32Issue(2) ：134-138,150.DOI:10.3969/j.issn.1671-038X.2024.02.09
✕
  • 维普
  • 万方数据

葛芩消溃方联合美沙拉嗪治疗溃疡性结肠炎疗效及相关机制初步探讨

Preliminary study on the efficacy and related mechanisms of Geqin Xiaokui Formula combined with mesalazine in the treatment of ulcerative colitis

贾靖 1徐甜甜 1张毅 1汪洋2
扫码查看

作者信息

  • 1. 惠州市第三人民医院消化内科(广东惠州,516000)
  • 2. 惠州市第三人民医院胃肠外科
  • 折叠

摘要

目的:探讨中药葛芩消溃方联合美沙拉嗪治疗溃疡性结肠炎(UC)临床疗效.方法:选择惠州市第三人民医院2019年6月-2022年12月收治的UC患者90例,随机分为观察组和对照组,每组45例,对照组接受美沙拉嗪肠溶片治疗,0.5 g/次,3次/d;观察组在此基础上予以中药葛芩消溃方治疗,疗程均为8周.比较2组治疗前后中医证候评分、Baron评分、结肠组织病理评分、Sutherland疾病活动指数评分,并比较2组血清D-乳酸、二胺氧化酶(DAO)、内毒素(ETX)水平和肠黏膜叉头框蛋白A2(FOXA2)mRNA、低氧诱导因子1α(HIF-1α)mRNA、微小核糖核酸-31-3p(miR-31-3p)表达情况,比较2组治疗总有效率和不良反应率.结果:治疗后观察组中医证候评分、Baron评分、结肠组织病理评分、Sutherland疾病活动指数评分均低于对照组(P＜0.01),血清D-乳酸、DAO、ETX水平均低于对照组(P＜0.01),黏膜组织FOXA2 mRNA表达量高于对照组(P＜0.01),HIF-1αmRNA、miR-31-3p表达量低于对照组(P＜0.01),治疗总有效率高于对照组(P＜0.05);2组不良反应率比较差异无统计学意义(P＞0.05).结论:葛苓消溃方联合美沙拉嗪可有效改善中医证候,保护肠黏膜功能,促进肠黏膜愈合,治疗UC效果显著,安全性好,其机制可能与调节黏膜组织FOXA2 mRNA、HIF-1α mRNA、miR-31-3p表达有关.

Abstract

Objective:To explore the clinical efficacy of Geqin Xiaokui Formula combined with mesalazine in the treatment of ulcerative colitis(UC).Methods:Ninety patients with UC admitted to our hospital from June 2019 to December 2022 were randomly divided into an observation group and a control group,with 45 patients in each group.The control group received mesalazine enteric-coated tablets,0.5 g each time,three times a day;The observation group was treated with Geqin Xiaokui Formula for 8 weeks.The traditional Chinese medicine(TCM)syndrome score,Baron score,colon histopathological score,Sutherland disease activity index score before and af-ter treatment were compared,and the levels of serum D-lactate,diamine oxidase(DAO),endotoxin(ETX),intes-tinal mucosal forkhead box protein A2(FOXA2)mRNA,and hypoxia-inducible factor-1α(HIF-1α)mRNA,Mi-croRNA-31-3p(miR-31-3p)expression were compared,and the total effective rate and adverse reaction rate of the two groups were compared.Results:After treatment,the TCM syndrome score,Baron score,colonic histopatho-logical score,and Sutherland disease activity index score of the observation group were lower than those of the control group(P＜0.01).The levels of D-lactic acid,DAO,and ETX in serum were lower than those of the con-trol group(P＜0.01),and the expression of FOXA2 mRNA in mucosal tissue was higher than that of the control group(P＜0.01).The expression of HIF-1α mRNA and miR-31-3p of the two groups was lower than that of the control group(P＜0.01),and the total effective rate of treatment was higher than that of the control group(P＜0.05).There was no statistically significant difference in the rate of adverse reactions between the two groups(P＞0.05).Conclusion:Geqin Xiaokui Formula combined with mesalazine can effectively improve traditional Chinese medicine syndromes,protect intestinal mucosal function,promote intestinal mucosal healing,and have a signifi-cant effect and safety in the treatment of UC.The mechanism may be related to the expression of regulation of mu-cosal organization FOXA2 mRNA and HIF-1α MRNA and miR-31-3p.

关键词

溃疡性结肠炎/中药/葛芩消溃方/美沙拉嗪/机制

Key words

ulcerative colitis/traditional Chinese medicine/Geqin Xiaokui Formula/mesalazine/mechanism

引用本文复制引用

出版年

2024
中国中西医结合消化杂志
华中科技大学同济医学院,中国中西医结合学会消化系统疾病专业委员会,中华中医药学会脾胃病专业委员会

中国中西医结合消化杂志

CSTPCD
影响因子：1.363
ISSN：1671-038X
参考文献量30
段落导航相关论文